Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Viking Therapeutics Inc

Start price
Target price
Perf. (%)
€69.50
29.04.24
€100.00
31.03.26
-0.75%
03.05.24

Could be very worthwhile Investment >20% year
buy
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€3.73
25.04.24
-
25.04.25
0.80%
27.04.24

Risky Investment
buy
Fate Therapeutics Inc.

Start price
Target price
Perf. (%)
€3.60
25.04.24
-
25.04.25
-2.00%
27.04.24

Could be worthwhile Investment >10% per year
buy
Fibrogen Inc.

Start price
Target price
Perf. (%)
€1.07
19.04.24
-
19.04.25
-10.90%
28.04.24

Could be very worthwhile Investment >20% year
buy
Viracta Therapeutics Inc.

Start price
Target price
Perf. (%)
€0.75
15.04.24
€3.00
31.10.25
-
15.04.24

Could be very worthwhile Investment >20% year
buy
aTyr Pharma Inc

Start price
Target price
Perf. (%)
€1.66
14.04.24
-
14.04.25
-13.86%
28.04.24

Could be worthwhile Investment >10% per year
Inotiv Inc.

Start price
Target price
Perf. (%)
€5.50
13.04.24
€4.00
13.04.25
-32.36%
27.04.24

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Little Investments for future growth
Nektar Therapeutics

Start price
Target price
Perf. (%)
€1.50
11.04.24
-
11.04.25
3.27%
14.04.24

Risky Investment
buy
Cytokinetics Inc.

Start price
Target price
Perf. (%)
€66.50
07.04.24
-
07.04.25
0.75%
14.04.24

Could be very worthwhile Investment >20% year
buy
Gritstone Oncology Inc

Start price
Target price
Perf. (%)
€1.11
02.04.24
-
02.04.25
-38.74%
16.04.24

Could be very worthwhile Investment >20% year
buy
Gritstone Oncology Inc

Start price
Target price
Perf. (%)
€1.14
02.04.24
-
02.04.25
-28.14%
13.04.24

Could be worthwhile Investment >10% per year
Gritstone Oncology Inc

Start price
Target price
Perf. (%)
€1.60
02.04.24
-
02.04.25
-48.88%
13.04.24

Probably not worthwhile Investment
Revenue decline/stagnation expected
Lower EBIT Margin than peer group
High valuation
Gritstone Oncology Inc

Start price
Target price
Perf. (%)
€2.64
28.03.24
-
28.03.25
-40.27%
31.03.24

Risky Investment
Gritstone Oncology Inc

Start price
Target price
Perf. (%)
€2.55
28.03.24
-
28.03.25
-38.27%
30.03.24

Could be worthwhile Investment >10% per year
Akebia Therapeutics Inc.

Start price
Target price
Perf. (%)
€1.88
26.03.24
-
26.03.25
-18.09%
31.03.24

Risky Investment
SELLAS Life Sciences Group Inc

Start price
Target price
Perf. (%)
€1.06
26.03.24
-
26.03.25
-1.69%
31.03.24

Risky Investment
Gritstone Oncology Inc

Start price
Target price
Perf. (%)
€2.57
21.03.24
-
21.03.25
-38.64%
31.03.24

Could be very worthwhile Investment >20% year
buy
Fibrogen Inc.

Start price
Target price
Perf. (%)
€2.22
21.03.24
-
21.03.25
2.97%
29.03.24

Probably not worthwhile Investment
buy
Akebia Therapeutics Inc.

Start price
Target price
Perf. (%)
€1.51
18.03.24
-
18.03.25
2.26%
30.03.24

Could be worthwhile Investment >10% per year
Akebia Therapeutics Inc.

Start price
Target price
Perf. (%)
€1.51
17.03.24
€0.30
30.11.25
76.96%
28.03.24

Could be very worthwhile Investment >20% year
Stoke Therapeutics Inc

Start price
Target price
Perf. (%)
€5.80
17.03.24
€3.00
31.01.26
60.34%
25.03.24

Could be very worthwhile Investment >20% year
buy
Verastem Inc.

Start price
Target price
Perf. (%)
€10.20
17.03.24
€16.00
30.06.26
-8.82%
19.03.24

Could be very worthwhile Investment >20% year
buy
Akebia Therapeutics Inc.

Start price
Target price
Perf. (%)
€1.51
16.03.24
€2.00
16.03.25
2.26%
30.03.24

Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Low dividend yield expected
buy
Chromadex Corp

Start price
Target price
Perf. (%)
€2.22
16.03.24
€4.00
16.03.25
53.15%
30.03.24

EBIT decline/stagnation expected
Revenue decline/stagnation expected
High valuation
Low dividend yield expected
buy
Novavax Inc.

Start price
Target price
Perf. (%)
€4.89
16.03.24
€48.00
16.03.25
-12.06%
30.03.24

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
Rising EBIT margin expected
Low dividend yield expected